Protagenic Therapeutics Stock Current Ratio
| PTIX Stock | USD 0.73 0.08 12.31% |
Protagenic Therapeutics fundamentals help investors to digest information that contributes to Protagenic Therapeutics' financial success or failures. It also enables traders to predict the movement of Protagenic Stock. The fundamental analysis module provides a way to measure Protagenic Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Protagenic Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 6.41 | 6.73 |
Protagenic | Current Ratio |
Protagenic Therapeutics Company Current Ratio Analysis
Protagenic Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Protagenic Therapeutics Current Ratio | 19.47 X |
Most of Protagenic Therapeutics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Protagenic Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Protagenic Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Protagenic Therapeutics is extremely important. It helps to project a fair market value of Protagenic Stock properly, considering its historical fundamentals such as Current Ratio. Since Protagenic Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Protagenic Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Protagenic Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Protagenic Current Ratio Historical Pattern
Today, most investors in Protagenic Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Protagenic Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Protagenic Therapeutics current ratio as a starting point in their analysis.
Protagenic Therapeutics Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Protagenic Therapeutics has a Current Ratio of 19.47 times. This is much higher than that of the Biotechnology sector and 178.14% higher than that of the Health Care industry. The current ratio for all United States stocks is notably lower than that of the firm.
Protagenic Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protagenic Therapeutics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protagenic Therapeutics could also be used in its relative valuation, which is a method of valuing Protagenic Therapeutics by comparing valuation metrics of similar companies.Protagenic Therapeutics is currently under evaluation in current ratio category among its peers.
Protagenic Fundamentals
| Return On Equity | -2.06 | ||||
| Return On Asset | -0.9 | ||||
| Current Valuation | (463.37 K) | ||||
| Shares Outstanding | 6.79 M | ||||
| Shares Owned By Insiders | 14.24 % | ||||
| Shares Owned By Institutions | 5.76 % | ||||
| Number Of Shares Shorted | 89.12 K | ||||
| Price To Earning | 9.43 X | ||||
| Price To Book | 6.10 X | ||||
| EBITDA | (4.5 M) | ||||
| Net Income | (5 M) | ||||
| Cash And Equivalents | 8.87 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 655.25 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 19.47 X | ||||
| Book Value Per Share | 0.83 X | ||||
| Cash Flow From Operations | (3.7 M) | ||||
| Short Ratio | 1.33 X | ||||
| Earnings Per Share | (1.27) X | ||||
| Target Price | 4.0 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 4.04 M | ||||
| Total Asset | 4.32 M | ||||
| Retained Earnings | (30.78 M) | ||||
| Working Capital | 3.54 M | ||||
| Current Asset | 3.75 M | ||||
| Current Liabilities | 736 K | ||||
| Net Asset | 4.32 M |
About Protagenic Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protagenic Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagenic Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagenic Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.